Treatment of chronic knee osteoarthritis with platelet lysis and platelet-rich plasma

Phase 3

Conditions: Knee Osteoarthritis.
Erosive (osteo)arthritis
M15.4

Registration Number: IRCT20160422027520N10

Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 25

Inclusion Criteria

Men and women between the ages of 18 and 75 with OA diagnosis based on the American College of Rheumatology
Analog scale of knee pain (VAS) equal to or greater than 2.5
People with at least 4 months of history of pain or swelling in one or both knees
Radiological classification scale Kellgren-Lawrence 1 or 2
The availability of individual during the study period
BMI Between 20 and 35

Exclusion Criteria

People under the age of 18 and over 75 years
Pregnant women or women who are breastfeeding
People with malignancy,People with severe heart disease, uncontrolled diabetes mellitus, rheumatoid arthritis, hemorrhagic diseases, history of anemia, arthritis, fibromyalgia and chronic fatigue syndrome
Those linked to acetaminophen or Vicodin or a history of drug misuse
History of cortisone injections in the last 6 weeks
The use of non-steroidal anti-inflammatory drugs 1 week ago
Having hemoglobin less than 11 g / dl and platelet count less than 150000 / mµ
The use of inhibitors of platelet aggregation and anti-coagulation such as heparin
History of knee surgery in the last 3 months
Extraordinary deformation (varus >5?, valgus >5?)

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Determining knee pain by VAS in all phases of clinical trial. Timepoint: 1 and 6 months after the first injection. Method of measurement: Questionnaire (Visual Analogue Scale).;Determination of knee function by Western Ontario and McMaster Universities Osteoarthritis Index in all phases of clinical trial. Timepoint: 1 and 6 months after the first injection. Method of measurement: Questionnaire (Western Ontario and McMaster Universities Osteoarthritis Index).;Determine the range of knee motion by manual joiniometry in all phases of clinical trial. Timepoint: 1 and 6 months after the first injection. Method of measurement: Range of motion (Degree).;Measurement of growth factors in platelet lysate and Platelet-rich plasma. Timepoint: 1 and 6 months after the first injection. Method of measurement: Elisa.

Secondary Outcome Measures